PMID- 14651473
OWN - NLM
STAT- MEDLINE
DCOM- 20040604
LR  - 20151119
IS  - 0143-5221 (Print)
IS  - 0143-5221 (Linking)
VI  - 106
IP  - 4
DP  - 2004 Apr
TI  - Plasma urocortin in human systolic heart failure.
PG  - 383-8
AB  - Urocortin (UCN), a member of the corticotrophin-releasing factor family, is 
      expressed in heart, brain and gut. UCN has potent cardiostimulatory, 
      cardioprotective, vasodilator and diuretic/natriuretic effects, and cardiac UCN 
      expression is increased in heart failure (HF). In the present study, we 
      investigated plasma levels of UCN in 119 patients with HF and 212 age- and 
      gender-matched controls to clarify its relationship with gender and disease 
      severity. UCN was elevated in HF [normal males, 19.5 (3.9-68.8) pmol/l and HF 
      males, 50.2 (6.9-108.2) pmol/l, P < 0.0005; normal females, 14.2 (3.9-53.5) 
      pmol/l and HF females, 21.8 (3.9-112.5) pmol/l, P < 0.001; values are medians 
      (range)]. The relative increase was greater in males than females ( P < 0.03). 
      UCN fell with increasing age, especially in HF patients ( r(s) = -0.56, P < 
      0.0005) and with increasing New York Heart Association (NYHA) class ( r(s) = 
      -0.55, P < 0.0005). The fall in UCN levels with increasing NYHA class was 
      reinforced by a significant correlation between UCN and ejection fraction ( r(s) 
      = 0.45, P < 0.0005) in HF patients. Although receiver operating characteristic 
      (ROC) curves for diagnosis of all HF cases yielded an area under the curve (AUC) 
      of 0.76, ROC AUCs for patients with early HF (NYHA class I and II) were better 
      (0.91). ROC AUCs for logistic models incorporating N-terminal probrain 
      natriuretic peptide (N-BNP) and UCN were better than either peptide alone. In 
      conclusion, plasma UCN is elevated in HF, especially in its early stages. Its 
      decline with increasing HF severity may expedite disease progression due to 
      diminished cardioprotective/anti-inflammatory effects. UCN measurement may also 
      complement N-BNP in the diagnosis of early HF.
FAU - Ng, Leong L
AU  - Ng LL
AD  - University of Leicester Department of Cardiovascular Sciences, Clinical Sciences 
      Building, Leicester Royal Infirmary, Leicester LE2 7LX, U.K. lln1@le.ac.uk
FAU - Loke, Ian W
AU  - Loke IW
FAU - O'Brien, Russell J
AU  - O'Brien RJ
FAU - Squire, Iain B
AU  - Squire IB
FAU - Davies, Joan E
AU  - Davies JE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Biomarkers)
RN  - 0 (Urocortins)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Area Under Curve
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Corticotropin-Releasing Hormone/*blood
MH  - Disease Progression
MH  - Female
MH  - Gender Identity
MH  - Heart Failure/*blood
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/analysis
MH  - Predictive Value of Tests
MH  - Systole
MH  - Urocortins
EDAT- 2003/12/04 05:00
MHDA- 2004/06/05 05:00
CRDT- 2003/12/04 05:00
PHST- 2003/12/03 00:00 [accepted]
PHST- 2003/11/03 00:00 [revised]
PHST- 2003/09/19 00:00 [received]
PHST- 2003/12/04 05:00 [pubmed]
PHST- 2004/06/05 05:00 [medline]
PHST- 2003/12/04 05:00 [entrez]
AID - CS20030311 [pii]
AID - 10.1042/CS20030311 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2004 Apr;106(4):383-8. doi: 10.1042/CS20030311.